Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 696 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis, Chronic Clear all

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir, Peginterferon α-2a; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Rialto, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: Chronic Hepatitis C
Interventions: valopicitabine, Pegylated Interferon Alfa; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 175 participants
Timeline: Started 2005
U.S. locations: 19
States / cities: Phoenix, Arizona • San Diego, California • San Mateo, California + 16 more

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Hepatitis B
Interventions: telbivudine, adefovir dipivoxil; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 3
States / cities: Atlanta, Georgia • Flushing, New York • Sterling, Virginia

Conditions: Chronic Hepatitis C
Interventions: telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: HBeAg-negative Chronic Hepatitis B
Interventions: TAF, TDF, TAF Placebo, TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 14
States / cities: Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more

Conditions: Hepatitis B
Interventions: GSK3228836, Nucleos(t)ide therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HCV Infection
Interventions: placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 48
States / cities: Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more

Conditions: Chronic Hepatitis C Infection
Interventions: Valacyclovir, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 3 more

Conditions: Hepatitis C Virus Infection
Interventions: Simeprevir, Sofosbuvir; Drug
Lead sponsor: Janssen Infectious Diseases BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 38
States / cities: Dothan, Alabama • Bakersfield, California • Chula Vista, California + 35 more

Conditions: Chronic Hepatitis C Infection, Fatty Liver
Interventions: Rosiglitazone and Pegasys/Ribavirin; Drug
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C
Interventions: NOV-205; Drug
Lead sponsor: Cellectar Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Jacksonville, Florida • Miami, Florida • Orlando, Florida + 3 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 25
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 21 more

Conditions: Hepatitis C
Interventions: BI 201335, PegIFN/RBV; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 20
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more

Conditions: Chronic Hepatitis C
Interventions: SCV-07; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 16
States / cities: Anaheim, California • Los Angeles, California • Palm Springs, California + 12 more

Conditions: Chronic Hepatitis B
Interventions: ABI-H2158 Reference Formulation, ABI-H2158 Test Formulation; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Chronic Hepatitis C
Interventions: BMS-650032, BMS-790052, BMS-791325, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 26
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 19 more

Conditions: Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney
Interventions: Post-transplant Grazoprevir and Elbasvir; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Hepatitis C
Interventions: GS-5816; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Thrombocytopenia
Interventions: Avatrombopag, Placebo, Pegylated interferon (PEG-IFN), Telaprevir, Ribavirin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • Fairfax, Virginia

Conditions: Chronic Hepatitis B
Interventions: Not listed
Lead sponsor: Medical Procare PLLC; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Los Angeles, California • San Jose, California • Flushing, New York + 2 more

Conditions: Chronic Hepatitis B
Interventions: AHB-137 injection, Placebo; Drug
Lead sponsor: AusperBio Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Redwood City, California • Baltimore, Maryland • New York, New York + 1 more

Conditions: Hepatitis C, Chronic Kidney Diseases, Patient Education
Interventions: Decision Aid; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

Transforming the Cascade Of Hepatitis C Care

Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

Herpes Simplex Type 1 Suppression in Hepatitis C

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients

A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B

Helping Empower Liver and Kidney Patients